ArcherDX and UCL extend TRACERx program collaboration to evaluate cancer evolution

ArcherDX and UCL extend TRACERx program collaboration to evaluate cancer evolution

BOULDER andLONDON -- ArcherDX, Inc. , UCL and the Francis Crick Institute today announced an extension to utilize personalized, liquid biopsy-based research assays for the duration of the TRACERx... Read More

Monday August 3, 2020 0 comments Tags: Boulder, ArcherDx, TRACERx, Jason Myers

ArcherDX and Invitae combine to create global leader in comprehensive cancer genetics and precision oncology

ArcherDX and Invitae combine to create global leader in comprehensive cancer genetics and precision oncology

BOULDER and SAN FRANCISCO– ArcherDX ,a leading genomics analysis company democratizing precision oncology, and San Francisco-based Invitae (NYSE: NVTA), a leading genetics company, today... Read More

Monday June 22, 2020 0 comments Tags: Boulder, ArcherDx, Invitae, Jason Myers, Sean George

ArcherDX collaborates with Bristol Myers Squibb to apply personalized cancer monitoring to clinical research

ArcherDX collaborates with Bristol Myers Squibb to apply personalized cancer monitoring to clinical research

BOULDER -- ArcherDX, Inc . announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM) assays to understand the potential benefits... Read More

Friday June 19, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers

ArcherDX announces strategic collaboration with AstraZeneca to develop personalized cancer monitoring assays

ArcherDX announces strategic collaboration with AstraZeneca to develop personalized cancer monitoring assays

BOULDER -- ArcherDX, Inc. , today announced a strategic collaboration with AstraZeneca to develop assays to support multiple planned Phase 3 clinical trials for AstraZeneca's targeted... Read More

Tuesday May 26, 2020 0 comments Tags: Boulder, ArcherDx, AstraZeneca, Jason Myers

ArcherDX and Bayer announce global collaboration to develop next-gen sequencing-based companion diagnostic for VITRAKVI

ArcherDX and Bayer announce global collaboration to develop next-gen sequencing-based companion diagnostic for VITRAKVI

BOULDER/BERLIN -- ArcherDX and Bayer today announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based companion diagnostic (CDx) for... Read More

Thursday May 14, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers, Bayer

ArcherDX appoints Jason Ryan to board of directors

ArcherDX appoints Jason Ryan to board of directors

BOULDER -- ArcherDX, Inc. has appointed Jason Ryan, chief operating and financial officer at Magenta Therapeutics and former chief financial officer at Foundation Medicine, to the company's board... Read More

Monday May 11, 2020 0 comments Tags: Boulder, ArcherDx, Jason Ryan, Jason Myers, Steve Kafka

ArcherDX and Premier Inc. partner to deliver personalized genomic testing to patients

ArcherDX and Premier Inc. partner to deliver personalized genomic testing to patients

BOULDER -- ArcherDX, Inc. and Premier Inc. , a leading healthcare improvement company,announced they have signed a two-part agreement, kicking off a multi-year program. Premier Applied... Read More

Tuesday April 21, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers, Premier Inc.

ArcherDX receives approval for Archer®MET Companion Diagnostic in advanced non-small cell lung cancer in Japan

ArcherDX receives approval for Archer®MET Companion Diagnostic in advanced non-small cell lung cancer in Japan

BOULDER -- ArcherDX, Inc. announced its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare and the Pharmaceutical Medical Devices Agency... Read More

Wednesday March 25, 2020 0 comments Tags: Boulder, ArcherDx, ArcherMET, Jason Myers